| 1 |
Collagen peptides Bovine / marine; branded Verisol®, Fortibone®, Peptan® |
Skin elasticity & wrinkles; hair/nails; joints; Fortibone-positioned bone density in postmenopausal women |
Global collagen peptides USD 1.84B (2025) [2]; collagen supplements Emergen USD 4.8B (2024) [5]. Fish collagen peptides GMI USD 715M (2024) / 850M (2025) [6]. GELITA ~15% of fish-collagen value (VERISOL, FORTIBONE, etc.) [6]. |
Mordor CAGR 8.43% (2026–31) [2]; fish collagen product-type CAGR 11.79% [2]. Trends “collagen peptides” UP ×4.11 [4]; “Verisol” UP ×1.26 [4]. |
Vital Proteins, Further Food, Sports Research, numerous private label; condition-specific SKUs with Verisol/Fortibone |
GELITA (Verisol, Fortibone, Tendoforte); Rousselot/Darling (Peptan); Nitta; Weishardt (Naticol); Thai Union (ThalaCol)
|
★★★★☆ 4 Multiple RCTs / skin meta-analyses exist; OA Europe PMC hit 2026 skin rejuvenation SR; brand dossiers strong. Peri/postmenopausal bone (Fortibone) clinical programme widely cited in trade — full papers not all re-fetched here. |
Competitor (same category) — also Complement if positioned as broader bioactive protein vs Type I/III-only |
| 2 |
Magnesium |
Sleep, calm, mood, muscle/nerve, bone co-factor — heavily used in midlife women’s stacks |
SPINS VMS 2024: magnesium functional ingredient $293.3M, dollar sales +40.9% [1]. Stress-category magnesium $10.2M +13.8% YoY (SPINS 52 wks to 14 Jul 2024 via NutraIngredients) [7]. |
Strong retail YoY; SPINS notes magnesium drove ~27% of growth in sleep/calm/mood subcats [1]. |
Natural Vitality Calm, Pure Encapsulations, numerous menopause multi blends |
Commodity + branded forms (bisglycinate, threonate, citrate) — Albion/Balchem, Magtein (threonate), etc. |
★★★★☆ 4 Broad clinical base for sleep/muscle; menopause-specific symptom RCTs mixed. Not re-fetched as a dedicated SR in this pass. |
Co-formulation / Complement |
| 3 |
Ashwagandha (Withania; KSM-66®, Sensoril®, etc.) |
Stress, sleep, mood; emerging menopause symptom support |
SPINS: ashwagandha in functional beverages +228.6% $ / +73.3% units (52 wks to 16 Jun 2024) [1]. Stress category still led by ashwagandha (exact $ for ashwagandha-only stress SKUs UNVERIFIED beyond beverage proxy). |
Trends “ashwagandha” UP ×2.24 [4]. |
Gaia Herbs, Olly, Moon Juice, many women’s multis |
Ixoreal (KSM-66), Natreon (Sensoril), Kerry/others |
★★★★☆ 4 2025 RCT (n=60, 56 days) menopause MRS primary endpoint — Europe PMC abstract fetched [8]. Stress literature extensive. |
Co-formulation (mood / stress stack) |
| 4 |
Vitamin D + calcium (± K2) |
Bone health; menopause bone-loss standard of care adjunct |
SPINS: Vitamin K $25.7M +44.9%; Vitamin A–D–K $12.2M +32.3% [1]. Calcium & bone called out as growing health focus [1]. Standalone vit D / calcium category totals UNVERIFIED (paywalled SPINS/NBJ detail). |
UP on K and A/D/K proxies [1]. |
Caltrate, Nature Made, menopause bone SKUs |
DSM-Firmenich, BASF, commodity calcium; MenaQ7 (K2) |
★★★★★ 5 Guideline-level bone evidence; CVD outcome meta-analyses more nuanced (fetched related vit D CVD SR abstract [europepmc list]). |
Co-formulation / Complement |
| 5 |
Omega-3 (EPA/DHA) |
Mood, heart, inflammation; bone marker data mixed |
Global omega-3 category size UNVERIFIED this session (not fetched). Persistent top women’s multi ingredient. |
Trends not batched for “omega-3”; retail remains mature mature / FLAT-to-modest (proxy). |
Nordic Naturals, Minimalist, menopause multis |
EPAX, KD Pharma, DSM, Arctic Nutrition |
★★★☆☆ 3 n-3 PUFA bone meta-analysis 2023: no overall BMD effect; some female/<60 subgroup signals [9]. Mood/CVD evidence stronger outside this fetch. |
Complement |
| 6 |
Soy / red clover isoflavones |
Vasomotor symptoms via phytoestrogen activity |
Embedded in many menopause SKUs (e.g. Legion Revitalize 100 mg soy isoflavones) [trade product pages]. Category $ UNVERIFIED. |
Trends “equol” (metabolite) UP ×13.85 [4] — rising interest in responders / S-equol. |
Estroven line variants, NOW, Legion Revitalize |
Frutarom/ICL, Archer Daniels, Novozymes (ferment), various |
★★★☆☆ 3 Large literature; effect sizes modest and heterogenous. Genistein CV risk-factor meta-analysis exists [europepmc]. |
Complement (different mechanism vs protein) |
| 7 |
Black cohosh Actaea / Cimicifuga |
Hot flashes, overall climacteric symptoms |
Long-standing menopause botanical; dollar volume UNVERIFIED. |
Trends “black cohosh” FLAT ×1.15 [4]. |
Remifemin, NOW Menopause Support, Legion Revitalize |
Euromed, Naturex/Givaudan, various extractors |
★★★☆☆ 3–4 2023 pairwise meta-analysis (22 RCTs, n=2,310): significant overall symptoms (Hedges’ g=0.575) and hot flashes (g=0.315) [10] — abstract fetched; full OA=N. |
Complement |
| 8 |
Whey / plant protein |
Lean mass, satiety; GLP-1 companion protein base |
Sports/active nutrition protein is large; exact women’s menopause split UNVERIFIED. Vitamin Shoppe GLP-1 Support Protein + myHMB is a visible 2024–25 format [11]. |
GLP-1 companion boom driving new protein SKUs [11][12]. |
The Vitamin Shoppe, Orgain, Ritual, women’s protein RTDs |
Glanbia, Arla, FrieslandCampina, pea protein suppliers |
★★★★☆ 4 Strong MPS evidence generally; menopause-specific dosing often extrapolated. |
Co-formulation / category Competitor for “protein occasion” |
| 9 |
EstroG-100® |
Multi-symptom menopause (hot flashes, mood, sleep, fatigue) without estrogen-receptor activity (per supplier) |
CK Ingredients (US distributor) reports menopause offerings doubled YoY [13]. Absolute $ UNVERIFIED. |
Strong supplier growth signal [13]; used in Doctor’s Best, California Gold Nutrition, Olly Mellow Menopause (EstroG cited in women’s health coverage). |
Doctor’s Best, CGN, Olly, Legion |
Naturalendo Tech (KR); CK Ingredients (US) |
★★★★☆ 4 Multiple RCTs cited in NutraIngredients (2022 climacteric; US KMI −62%); not all papers re-fetched OA this session [13]. |
Complement / Co-formulation (vasomotor + Ovitage structural protein) |
| 10 |
Pollen extract Serelys® / Relizen® / Femal |
Vasomotor symptoms (non-hormonal) |
Flagship of Bonafide Relizen; Bonafide acquired by Pharmavite for $425M (2023) per NutraIngredients women’s health article context [search/snippet — confirm paywalled body]. Relizen-specific retail $ UNVERIFIED. |
Established Rx-adjacent OTC; momentum more brand than ingredient search. |
Bonafide Relizen; Estroven/Femal variants internationally
|
Sérélys Pharma / pollen IP holders; Bonafide / Pharmavite distribution |
★★★☆☆ 3 2024 SR/meta-analysis on purified pollen extract for VMS — abstract fetched [14]; OA=N. |
Complement |
| 11 |
Probiotics / women’s strains |
Gut, vaginal, mood–gut axis; menopause microbiome interest |
US women’s digestive health cited ~$52M (−19%) in SPINS women’s-health breakout via NutraIngredients UNVERIFIED in fetched body (article truncated/paywalled). |
Mixed YoY; postbiotics rising (see rising table). |
Garden of Life, Fem-Dophilus, Bonafide Clairvee |
Chr. Hansen, ADM/Deerland, Lallemand, Seed |
★★★☆☆ 3 Strain-specific; menopause RCTs growing but heterogeneous. |
Co-formulation (gut claim stack) |
| 12 |
Maca |
Libido, energy, “hormone balance” (marketing) |
Category $ UNVERIFIED. |
Trends “maca” FLAT ×1.13 [4]. |
Theotex, Garden of Life, women’s blends |
Naturex, various Peruvian suppliers |
★★☆☆☆ 2 Small/heterogeneous RCTs; evidence weak vs cohosh/isoflavones. |
Complement (weak) |
| 13 |
Evening primrose oil (GLA) |
Breast tenderness, skin; hot-flash evidence weak |
$ UNVERIFIED. |
Trends “evening primrose” UP ×1.32 [4] — search interest persists despite mixed evidence. |
Nature’s Way, Holland & Barrett staple |
Various oil processors |
★★☆☆☆ 2 Often included historically; VMS evidence generally disappointing in modern reviews (not re-fetched). |
Low relevance |
| 14 |
Saffron (affron®, etc.) |
Mood, low mood, PMS/menopause mood support |
$ UNVERIFIED. |
Trends “saffron supplement” UP ×15.09 [4] — sharp search rise. |
Mood SKUs; women’s calm blends |
Pharmactive (affron), other extractors |
★★★☆☆ 3 Mood RCTs exist; menopause-specific base thinner than ashwagandha. |
Co-formulation (brain fog / mood) |